Upgrade to SI Premium - Free Trial

Alnylam Pharma (ALNY)

253.01 -0.06 (0.02%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/6/25)

Latest Headlines

Is Trump 2.0 good or bad for healthcare stocks? November 30, 2024 4:00 AM - StreetInsider Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 25 Filed by: Greenstreet Yvonne November 27, 2024 5:23 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 25 Filed by: Garg Pushkal November 27, 2024 5:22 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 25 Filed by: Poulton Jeffrey V. November 27, 2024 5:22 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 25 Filed by: Tanguler Tolga November 27, 2024 5:21 PM - SEC Filing Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 25 Filed by: Fitzgerald Kevin Joseph November 27, 2024 5:21 PM - SEC Filing Form 144 ALNYLAM PHARMACEUTICALS, Filed by: Fitzgerald Kevin Joseph November 27, 2024 4:07 PM - SEC Filing Alnylam to Webcast Presentation at Piper Sandler 36th Annual Healthcare Conference November 27, 2024 7:00 AM - BizWire Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) November 26, 2024 6:52 AM - StreetInsider BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) November 25, 2024 8:23 AM - StreetInsider Alnylam Pharma (ALNY) Announces U.S. FDA Acceptance of sNDA for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy November 25, 2024 7:01 AM - StreetInsider Alnylam Announces U.S. Food and Drug Administration Acceptance of Supplemental New Drug Application for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy November 25, 2024 7:00 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) November 19, 2024 6:54 AM - StreetInsider TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) November 18, 2024 8:56 AM - StreetInsider Alnylam Announces Interim Phase 1 Data of Nucresiran (ALN-TTRsc04) Showing Rapid Knockdown of TTR that is Sustained at Six Months Following a Single Dose November 17, 2024 9:30 AM - BizWire Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: FMR LLC November 12, 2024 9:51 AM - SEC Filing Wolfe Research Downgrades Alnylam Pharmaceuticals (ALNY) to Underperform November 11, 2024 4:35 PM - StreetInsider Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: WELLINGTON MANAGEMENT GROUP LLP November 8, 2024 10:35 AM - SEC Filing Alnylam to Webcast Presentations at Upcoming November Investor Conferences November 4, 2024 8:00 AM - BizWire H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) November 4, 2024 6:50 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $310 at Scotiabank November 1, 2024 8:37 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $275 at Wells Fargo November 1, 2024 6:57 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $384 at Canaccord Genuity November 1, 2024 6:50 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $329 at Barclays November 1, 2024 3:12 AM - StreetInsider Form 10-Q ALNYLAM PHARMACEUTICALS, For: Sep 30 October 31, 2024 8:23 AM - SEC Filing Form 8-K ALNYLAM PHARMACEUTICALS, For: Oct 31 October 31, 2024 8:11 AM - SEC Filing Alnylam Pharma (ALNY) Tops Q3 EPS by 43c, Misses on Revenue; Offers FY24 Guidance October 31, 2024 8:05 AM - StreetInsider Alnylam Pharmaceuticals Reports Third Quarter 2024 Financial Results and Highlights Recent Period Activity October 31, 2024 8:00 AM - BizWire Alnylam to Showcase Latest Data from TTR Franchise and Hypertension Program at American Heart Association Scientific Sessions 2024 October 30, 2024 8:00 AM - BizWire Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) October 24, 2024 6:23 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $371 at TD Cowen October 21, 2024 8:21 AM - StreetInsider H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) October 18, 2024 6:42 AM - StreetInsider Alnylam to Webcast Conference Call Discussing Third Quarter 2024 Financial Results October 17, 2024 8:00 AM - BizWire Alnylam Pharma (ALNY) Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy October 16, 2024 8:04 AM - StreetInsider Alnylam Submits Regulatory Application to the European Medicines Agency for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy October 16, 2024 8:00 AM - BizWire Scotiabank Starts Alnylam Pharmaceuticals (ALNY) at Sector Outperform October 16, 2024 5:26 AM - StreetInsider Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) October 11, 2024 6:20 AM - StreetInsider Form 4 ALNYLAM PHARMACEUTICALS, For: Oct 08 Filed by: Garg Pushkal October 10, 2024 4:06 PM - SEC Filing TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) October 10, 2024 8:21 AM - StreetInsider BMO Capital Reiterates Outperform Rating on Alnylam Pharmaceuticals (ALNY) October 10, 2024 7:56 AM - StreetInsider Piper Sandler Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY) October 10, 2024 7:43 AM - StreetInsider Oppenheimer Reiterates Perform Rating on Alnylam Pharmaceuticals (ALNY) October 10, 2024 6:25 AM - StreetInsider Citi Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) October 10, 2024 5:50 AM - StreetInsider Goldman Sachs Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) October 10, 2024 5:36 AM - StreetInsider BofA Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) October 10, 2024 5:30 AM - StreetInsider Alnylam Pharma (ALNY) Submits sNDA to FDA for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy October 9, 2024 7:03 AM - StreetInsider Alnylam Submits Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for Vutrisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy October 9, 2024 7:00 AM - BizWire Form 4 ALNYLAM PHARMACEUTICALS, For: Oct 01 Filed by: Hesslein Robert W. October 3, 2024 4:12 PM - SEC Filing Form 3 ALNYLAM PHARMACEUTICALS, For: Sep 30 Filed by: Hesslein Robert W. October 3, 2024 4:09 PM - SEC Filing Canaccord Genuity Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) October 1, 2024 6:49 AM - StreetInsider TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) September 30, 2024 8:35 AM - StreetInsider Piper Sandler Reiterates Overweight Rating on Alnylam Pharmaceuticals (ALNY) September 30, 2024 7:52 AM - StreetInsider Goldman Sachs Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) September 30, 2024 5:42 AM - StreetInsider Alnylam Highlights New Data From HELIOS-B Study of Vutrisiran for the Treatment of Transthyretin Amyloidosis With Cardiomyopathy at Heart Failure Society of America Annual Scientific Meeting 2024 September 29, 2024 9:00 AM - BizWire BofA Securities Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) September 27, 2024 6:01 AM - StreetInsider Alnylam to Webcast TTR Investor Day September 26, 2024 8:00 AM - BizWire China Merchants Securities Starts Alnylam Pharmaceuticals (ALNY) at Buy September 20, 2024 11:35 AM - StreetInsider TD Cowen Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY) September 16, 2024 8:41 AM - StreetInsider Alnylam Pharmaceuticals (ALNY) PT Raised to $307 at BofA Securities September 4, 2024 5:22 AM - StreetInsider Full Article List